J&J Sets The Pace In Race To $10bn RSV Vaccine Market
80% Efficacy Against Severe Disease In 65+ Group
Executive Summary
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.
You may also be interested in...
GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial
GSK has declared success for its RSV vaccine and will begin regulatory talks immediately – but the final efficacy level, as yet unrevealed, could be decisive in a competitive market.
Recent US FDA Breakthrough Therapy Designations, From Mass Market Vaccines To Rare Diseases
Merck’s latest pneumococcal vaccine and Pfizer’s RSV vaccine notched new BTDs, along with Zambon’s inhaled antibiotic for non-CF bronchiectasis, Acer’s vascular Ehlers-Danlos syndrome drug and Dizal’s targeted lung cancer candidate.
GSK Gets A Lucky Q1 Boost, But All Eyes Are On RSV Vaccine Readout
GlaxoSmithKline has just acquired a late-stage oncology asset, and sales of Shingrix are on the up again, but the outcome of its RSV vaccine study remains the main focus for 2022.